LAIS Trial: Can Loberamisal Transform Stroke Recovery?
Effective neuroprotective therapies remain an elusive goal in vascular neurology. Consequently, clinicians urgently need agents that can protect ischemic tissue and support neurological repair. The landmark phase 3 LAIS trial assessed the efficacy of loberamisal in acute stroke. Conducted across 32 medical centers in China, the study evaluated whether this dual-target agent improves long-term outcomes.
Evaluating Loberamisal in Acute Stroke
Investigators enrolled 998 adult patients who presented within 48 hours of symptom onset. Specifically, eligible participants presented with baseline National Institutes of Health Stroke Scale scores between 7 and 20. In addition, patients had no significant prestroke functional disability. Clinicians randomized participants equally to receive either daily intravenous loberamisal (40 mg) or matching placebo for 10 consecutive days. Moreover, all patients received standard background stroke care throughout the study period. Ultimately, 997 patients received at least one study dose and completed the primary analysis.
Dual Mechanism of Action
Most past neuroprotective trials failed because they targeted only a single pathophysiological pathway. In contrast, loberamisal introduces an innovative dual-action approach to neuroprotection. The small molecule disrupts the postsynaptic density 95 pathway to reduce excitotoxic cell death. Furthermore, it potentiates alpha-2 gamma-aminobutyric acid type A receptors. This synergistic action diminishes both neuronal injury and severe neuroinflammation. Therefore, the agent promotes functional recovery beyond the narrow hyperacute reperfusion window.
Key Findings from the LAIS Trial
The trial defined the primary outcome as a 90-day modified Rankin Scale score of 0 to 1. Notably, 69.7% of patients in the loberamisal group achieved this outcome compared with 56.3% in the placebo group. This demonstrated a statistically significant relative risk of 1.24 and an absolute risk difference of 13.28%. Additionally, the investigators observed comparable safety outcomes between the two treatment arms. Overall adverse events occurred in 87.8% of the loberamisal group and 88.7% of the placebo group. Serious adverse events affected 8.6% of loberamisal recipients versus 10.7% on placebo. Furthermore, all-cause mortality remained low at 1.2% with loberamisal and 2.0% with placebo.
Clinical Implications for Practice
Thrombolysis and thrombectomy remain inaccessible for many patients due to late hospital presentation. Because loberamisal showed efficacy within a 48-hour window, it could significantly widen treatment opportunities. Consequently, this therapy provides hope for patients ineligible for acute reperfusion interventions. However, clinicians must await confirmatory global trials before routinely adopting this regimen. Future studies will also clarify whether these benefits translate across diverse ethnic populations.
Frequently Asked Questions
Q1: What is loberamisal and how does it function?
Loberamisal is an investigational small molecule that dually targets the PSD-95 pathway and alpha-2 GABAA receptors to limit excitotoxicity and reduce neuroinflammation.
Q2: What functional recovery outcomes did the LAIS trial report?
At 90 days, 69.7% of participants receiving loberamisal attained full functional independence (mRS 0-1) compared with 56.3% of individuals receiving placebo.
Q3: What treatment window was evaluated in the LAIS trial?
The trial enrolled patients within 48 hours of symptom onset, administering intravenous therapy once daily for 10 consecutive days.
References
- Li S et al. Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial. JAMA. 2026 Sep 10. doi: 10.1001/jama.2026.16557. PMID: 42721021.
- Li S, Zhang Y, Wang Y, et al. Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial. Stroke Vasc Neurol. 2025;svn-2025-004582. doi: 10.1136/svn-2025-004582.
